Top Markets
#1 DogBull DogBull +107.71%
#2 MarsCoin MarsCoin +63.63%
#3 ADO Protocol ADO Protocol +52.07%
#4 Siacoin Siacoin +42.87%
#5 Ontology Gas Ontology Gas +24.40%
#6 The Bitcoin Bull The Bitcoin Bull +17.58%
#7 Apertum Apertum +15.01%
#8 Useless Coin Useless Coin +13.70%
#9 UnifAI Network UnifAI Network +12.09%
#10 Nockchain Nockchain +11.09%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Kedudukan dalam Saham #15114
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Harga Saham
$4.74
Disegerakkan terakhir: 2026-08-31
Modal Pasaran
$372.19M
Perubahan (1 hari)
-2.47%
Perubahan (1 tahun)
-1.04%
Negara
US
Perdagangan Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategori

Healthcare
Pendapatan untuk Lexeo Therapeutics, Inc. Common Stock (LXEO)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Lexeo Therapeutics, Inc. Common Stock, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Lexeo Therapeutics, Inc. Common Stock dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH